Emergent BioSolutions Valuation
Is EBS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EBS ($8.6) is trading below our estimate of fair value ($284.85)
Significantly Below Fair Value: EBS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EBS?
Key metric: As EBS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EBS's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | US$1.13b |
| Market Cap | US$418.30m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -196.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EBS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.7x | ||
CVAC CureVac | 8.3x | -7.4% | US$569.8m |
SGMO Sangamo Therapeutics | 7.6x | 38.0% | US$427.7m |
EXAI Exscientia | 28.5x | 9.5% | US$613.9m |
AKBA Akebia Therapeutics | 2.3x | 27.1% | US$390.5m |
EBS Emergent BioSolutions | 0.4x | -0.7% | US$418.3m |
Price-To-Sales vs Peers: EBS is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (11.7x).
Price to Sales Ratio vs Industry
How does EBS's PS Ratio compare vs other companies in the US Biotechs Industry?
| 145 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 10.3x | 20.8% | |
EBS Emergent BioSolutions | 0.4x | -0.7% | US$418.30m |
AMGN Amgen | 4.6x | 2.4% | US$152.45b |
GILD Gilead Sciences | 3.9x | 2.4% | US$110.17b |
| 145 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 10.3x | 26.7% | |
EBS Emergent BioSolutions | 0.4x | 98.5% | US$418.30m |
Price-To-Sales vs Industry: EBS is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Biotechs industry average (10.3x).
Price to Sales Ratio vs Fair Ratio
What is EBS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | 2.3x |
Price-To-Sales vs Fair Ratio: EBS is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.6b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.49
7D
-5.1%
1Y
74.5%
Collegium Pharmaceutical
US$954.0m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$29.22
7D
-9.2%
1Y
14.2%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$55.25
7D
-10.5%
1Y
7.7%